1-4 of 4
Finn Wisløff
Close
Sort by
Journal Articles

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Clinical Trials & Observations
Anders Waage, Peter Gimsing, Peter Fayers, Niels Abildgaard, Lucia Ahlberg, Bo Björkstrand, Kristina Carlson, Inger Marie Dahl, Karin Forsberg, Nina Gulbrandsen, Einar Haukås, Øyvind Hjertner, Martin Hjorth, Torbjörn Karlsson, Lene Meldgaard Knudsen, Johan Lanng Nielsen, Olle Linder, Ulf-Henrik Mellqvist, Ingerid Nesthus, Jürgen Rolke, Maria Strandberg, Jon Hjalmar Sørbø, Finn Wisløff, Gunnar Juliusson, Ingemar Turesson, for the Nordic Myeloma Study Group
Journal: Blood
Blood (2010) 116 (9): 1405–1412.
https://doi.org/10.1182/blood-2009-08-237974
Published: 2010
Journal Articles

Randomised Study on Prophylactic Pamidronate 30 mg vs. 90 mg in Multiple Myeloma (Nordic Myeloma Study Group).

Peter Gimsing, MD, Kristina Carlson, MD, Peter Fayers, Ingemar Turesson, MD, Finn Wisløff
Journal: Blood
Blood (2007) 110 (11): 533.
https://doi.org/10.1182/blood.V110.11.533.533
Published: 2007
Journal Articles

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

Monica Galli, Giovanna Borrelli, Eva Marie Jacobsen, Rosa Maria Marfisi, Guido Finazzi, Roberto Marchioli, Finn Wisloff, Stefana Marziali, Olivier Morboeuf, Tiziano Barbui
Journal: Blood
Blood (2007) 110 (4): 1178–1183.
https://doi.org/10.1182/blood-2007-01-066043
Published: 2007
Includes: Supplemental data
Journal Articles

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor

Clinical Trials & Observations
Therese Standal, Magne Borset, Stig Lenhoff, Finn Wisloff, Berit Stordal, Anders Sundan, Anders Waage, Carina Seidel
Journal: Blood
Blood (2002) 100 (12): 3925–3929.
https://doi.org/10.1182/blood-2002-05-1406
Published: 2002